Knowledge graph · Drug
Mirdametinib
small molecule
- Identifier
- CI-DRUG-00000379
- Entity page
- /drug/mirdametinib ↗
- Edges
- 66
- Neighbours
- 20 cancers2 genes7 variants10 trials1 approvals
- Drawn
- 40 of 40 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Mirdametinib approved for …APPROVED_FORderived1 of 1 | ||||||||
| → approved for | EMA · EU · 2025Ezmekly as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric and adult patients with neurofibromatosis type 1 (NF1) aged 2 years and above. EMA (EU) · approved · 2025-07-17 · Ezmekly as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric and adult patie… | — | approved | not mapped | 1 | Regulatory | ema | open ↗ |
| Mirdametinib predicts response to … | ||||||||